Department of Biochemistry, Nizam s Institute of Medical Sciences, Punjagutta, Hyderabad.

Similar documents
AGE-SPECIFIC REFERENCE RANGES FOR SERUM PROSTATE-SPECIFIC ANTIGEN IN BLACK MEN. The New England Journal of Medicine

Enzyme Immunoassay for the Quantitative Determination of Free Prostate Specific Antigen (f-psa) in Human Serum

Age-specific reference ranges for prostate-specific antigen (PSA) in Jordanian patients

KEY WORDS : Total Prostate Specific Antigen, Prostatic Acid Phosphatase, Benign Prostatic Hyperplasia, Prostate Cancer, and Sudanese.

Age Specific Reference Levels of Serum. Volume and Prostate Specific Antigen. Density in Healthy Iranian Men

Although the test that measures total prostate-specific antigen (PSA) has been

Utility of free/total prostate specific antigen (f/t PSA) ratio in diagnosis of prostate carcinoma

Age-Related Prostate Specific Antigen Reference Ranges in Healthy Northern Iranian Men

The Prostate Specific-Antigen (PSA):

BPH & Male LUTS INJ 2010;14:

Kathmandu University Medical Journal (2010), Vol. 8, No. 2, Issue 30,

Review of Clinical Manifestations of Biochemicallyadvanced Prostate Cancer Cases

Age-specific serum prostate-specific antigen references range among healthy men in Port Harcourt, Nigeria: a retrospective hospital-based study

Contribution of prostate-specific antigen density in the prediction of prostate cancer: Does prostate volume matter?

Practice Patterns of Korean Urologists for Screening and Managing Prostate Cancer according to PSA Level

Original Article - Urological Oncology. Ho Gyun Park 1, Oh Seok Ko 1, Young Gon Kim 1, Jong Kwan Park 1-4

Distribution of prostate specific antigen (PSA) and percentage free PSA in a contemporary screening cohort with no evidence of prostate cancer

Preparation of prostate specific antigen standards for immunoradiometric assay

Age-Specific Reference Ranges for PSA in the Detection of Prostate Cancer

Evaluation of Prostate Specific Antigen as a Tumor Marker in Cancer Prostate

Prostate Specific Antigen in a Community-Based Sample of Men Without Prostate Cancer: Correlations With Prostate Volume, Age, Body

The Prostate Cancer Detection Rate on the Second Prostate Biopsy according to Prostate-Specific Antigen Trend

Age-specific reference levels of serum prostate-specific antigen and prostate volume in healthy Arab men

Subject Review. Percent Free Prostate-Specific Antigen: Entering a New Era in the Detection of Prostate Cancer

NIH Public Access Author Manuscript World J Urol. Author manuscript; available in PMC 2012 February 1.

SERUM PROSTATE SPECIFIC ANTIGEN LEVELS IN MEN WITH BENIGN PROSTATIC HYPERPLASIA AND CANCER OF PROSTATE. A. AMAYO and W.

Correlation of Gleason Scores Between Needle-Core Biopsy and Radical Prostatectomy Specimens in Patients with Prostate Cancer

Table 1. Descriptive characteristics, total prostate-specific antigen, and percentage of free/total prostate-specific antigen distribution Age Groups

Complexed Prostate-specific Antigen for the Detection of Prostate Cancer

Use of the Percentage of Free Prostate-Specific Antigen to Enhance Differentiation of Prostate Cancer From Benign Prostatic Disease

Safety and Efficacy of Combined Transrectal Ultrasound-Guided Prostate Needle Biopsy and Transurethral Resection of the Prostate

The first and only fully-automated, multiplexed solution for Measles, Mumps, Rubella and Varicella-zoster virus antibody testing

When PSA fails. Urology Grand Rounds Alexandra Perks. Rising PSA after Radical Prostatectomy

Prostate Cancer Screening Guidelines in 2017

Use of early PSA velocity to predict eventual abnormal PSA values in men at risk for prostate cancer {

Asian J Androl 2005; 7 (2): DOI: /j x

Histopathological Study of Transrectal Ultrasound Guided Biopsies of Prostate

Subject Review. Prostate-Specific Antigen: Critical Issues for the Practicing Physician

ISSN X (Print) Pradesh. *Corresponding author Dr. Ashish

Repeating an abnormal prostate-specific antigen (PSA) level: how relevant is a decrease in PSA?

Are Prostate Carcinoma Clinical Stages T1c and T2 Similar?

One of the most important clinical applications of

Post Radical Prostatectomy Radiation in Intermediate and High Risk Group Prostate Cancer Patients - A Historical Series

Prostate Gland Volume and Its Relationship to Complications of Benign Prostatic Enlargement

Outcomes of Radical Prostatectomy in Thai Men with Prostate Cancer

COMPARATIVE STUDY OF BIOCHEMICAL MARKERS IN PROSTATITIS, BENIGN PROSTATE HYPERTROPHY AND CARCINOMA OF PROSTATE WITH AND WITHOUT METASTASIS

or more transrectal ultrasonography (TRUS)-guided ng/ml and 39% if it was 20.0 ng/ml. of >10 ng/ml have prostate cancer [3], many other

Role of Prostate-Specific Antigen Change Ratio at Initial Biopsy as a Novel Decision-Making Marker for Repeat Prostate Biopsy

Infectious Disease Testing. ULTRA Product Line. Safety is not a Matter of Chance

INTEROBSERVER VARIATION OF PROSTATIC VOLUME ESTIMATION WITH DIGITAL RECTAL EXAMINATION BY UROLOGICAL STAFFS WITH DIFFERENT EXPERIENCES

Effect of Verification Bias on Screening for Prostate Cancer by Measurement of Prostate-Specific Antigen

ORIGINAL ARTICLE. Ja Hyeon Ku 1, Kyung Chul Moon 2, Sung Yong Cho 1, Cheol Kwak 1 and Hyeon Hoe Kim 1

Clinical Use of Tumor Markers Based on Outcome Analysis

ab Human Annexin A10 ELISA Kit

Determination of An Optimum Cut-off Point for % fpsa/tpsa to Improve Detection of Prostate Cancer

Prothrombin (Human) ELISA Kit

Since the beginning of the prostate-specific antigen (PSA) era in the. Characteristics of Insignificant Clinical T1c Prostate Tumors

Tumor marker α-fetoprotein receptor does not discriminate between benign prostatic disease and prostate cancer

Evaluation of a rapid qualitative prostate speci c antigen assay, the One Step PSA TM test

Prostate-Specific Antigen in 2006: Effective Use in Benign Prostatic Hyperplasia and Prostate Cancer

PREVALENCE OF PROSTATE CANCER AMONG HYPOGONADAL MEN WITH PROSTATE-SPECIFIC ANTIGEN LEVELS OF 4.0 ng/ml OR LESS

Introduction. Objective To investigate the clinical significance of the 1.13 ng/ml, P<0.001) and a lower free-to-total PSA

Pathologic characteristics of prostatic adenocarcinomas: a mapping analysis of Korean patients

THE SIGNIFICANCE OF HYPOECHOIC LESION DIRECTED AND TRANSITION ZONE BIOPSIES IN IMPROVING THE DIAGNOSTIC ABILITY IN PROSTATE CANCER

Screening for prostatic carcinoma: case finding is not the problem

Original Article. Introduction. Xin LIU 1, *Jie TANG 2, Xiang FEI 2, Qiu-Yang LI 2

Optimal Baseline Prostate-Specific Antigen Level to Distinguish Risk of Prostate Cancer in Healthy Men Between 40 and 69 Years of Age

Urological Oncology. Sung Woon Park, Chul Sung Kim 1, Gilho Lee 2. DOI: /kju INTRODUCTION

Elevated PSA. Dr.Nesaretnam Barr Kumarakulasinghe Associate Consultant Medical Oncology National University Cancer Institute, Singapore 9 th July 2017

Prostate Cancer Screening: Risks and Benefits across the Ages

Prostate disorders in an apparently normal Nigerian population 2: Relationship with some biochemical parameters

Original Article Age-specific reference range of prostate-specific antigen in a population-based single-center study in the north of China

NEURO-FUZZY SYSTEM FOR PROSTATE CANCER DIAGNOSIS LUIGI BENECCHI

AssayMax Human Aldose Reductase ELISA Kit

Prostate-Specific Antigen as a Marker of Disease Activity in Prostate Cancer: Part 1

Associations Between Diabetes and Clinical Markers of Benign Prostatic Hyperplasia among Community-Dwelling Black and White Men

Is Prostate Biopsy Essential to Diagnose Prostate Cancer in the Older Patient with Extremely High Prostate-Specific Antigen?

colorimetric sandwich ELISA kit datasheet

Clinical audit. symptoms in general practice. An audit of prostate-specific antigen and clinical

A Summary of Childhood Cancer Statistics in Australia,

Increasing Awareness, Diagnosis, and Treatment of BPH, LUTS, and EP

Human LDL ELISA Kit. Innovative Research, Inc.

PREVALENCE OF PROSTATE ADENOCARCINOMA ACCORDING TO RACE IN AN UNIVERSITY HOSPITAL

Controversies in Prostate Cancer Screening

Chymotrypsin ELISA Kit

Prognostic Significance of Prostate Specific Antigen in Comparison with Histological Grade of Prostatic Adenocarcinoma: A Hospital Based Study

Results you can trust

of Nebraska - Lincoln

Human TSH ELISA Kit. User Manual

colorimetric sandwich ELISA kit datasheet

α-blocker Monotherapy and α-blocker Plus 5-Alpha-Reductase Inhibitor Combination Treatment in Benign Prostatic Hyperplasia; 10 Years Long-Term Results

Design and Analysis of a Cancer Prevention Trial: Plans and Results. Matthew Somerville 09 November 2009

The Prognostic Importance of Prostate-Specific Antigen in Monitoring Patients Undergoing Maximum Androgen Blockage for Metastatic Prostate Cancer

A Design of Efficient Medical Information System to Enhance Health Behaviors after Radical Prostatectomy

ab Cathepsin D Human ELISA Kit

ab Human Annexin A1 ELISA Kit

Mouse Cathepsin B ELISA Kit

Mouse Adiponectin Immunoassay Kit

Prostate-Specific Antigen Testing of Older Men

ab Leptin Human ELISA Kit

Transcription:

RACIAL AND ETHNIC VARIATION OF PSA IN GLOBAL POPULATION: AGE SPECIFIC REFERENCE INTERVALS FOR SERUM PROSTATE SPECIFIC ANTIGEN IN HEALTHY SOUTH INDIAN MALES T.Malati and G.Rajani Kumari Department of Biochemistry, Nizam s Institute of Medical Sciences, Punjagutta, Hyderabad. ABSTRACT The serum PSA is universally accepted as the useful and clinically relevant tumor marker for monitoring therapy and identifying early recurrence in patients of carcinoma prostate throughout the world. However, application of serum PSA is limited to screening for early adenocarcinoma prostate among males above fifty years of age. Serum PSA concentration varies from one population to another in different parts of the world. Many groups of workers have selected 4 ng/ml of serum PSA as upper limit of normal range without giving due consideration for age specific increase in serum PSA. There is no single report available on normal decade wise age specific reference intervals for serum PSA in Indian males. The present study is undertaken to establish age specific reference intervals in healthy Indian males from 20-89 years belonging to subpopulation of Andhra Pradesh from South India. Our results revealed lowest concentration of 95 percentile serum PSA in Indian males compared to other populations globally. Contrary to this, healthy Afro Americans were found to have highest concentration of serum PSA compared to all other populations. KEY WORDS Serum PSA, Healthy Indian males, reference intervals, Age specific PSA INTRODUCTION Prostate specific antigen is the useful and clinically relevant tumor marker for the diagnosis and management of prostate cancer. Unlike other tumor markers, prostate specific antigen (PSA) as the name indicates, is organ specific. PSA, synthesized by the epithelial cells lining the acini and ducts of the prostate gland is secreted via ductal system of prostate and stored in high concentration in seminal fluid. Under normal physiological condition it is present in lower concentration in circulation. With the help of sensitive enzyme immunoassays low levels of serum PSA are detected in healthy men of all races. Several studies have reported varying concentrations of PSA in serum of healthy males belonging to different races, ethnic groups and populations (1-4). It is relevant to highlight that there is not a single report on either 95 percentile value (upper limit of normal range) or on appropriate reference intervals for serum PSA in Indian population. Hence it was felt mandatory to establish our own reference ranges, in particular, Author for Correspondence : Dr. T. Malati Department of Biochemistry, Nizam s Institute of Medical Sciences, Punjagutta, Hyderabad. the 95 percentile for healthy Indian men in order to interpret the PSA results in benign as well as malignant disorders of prostate in Indian patients. Efforts were also made to establish age specific reference intervals for serum PSA concentrations because of the observation that it increases with advancing age in different populations (4-6) MATERIALS AND METHODS Our study groups consisted of 583 healthy subjects (belonging to subpopulation of Andhra Pradesh from South India) of different age groups ranging from 19 years to 89 years. Subjects with any urological complications were excluded from the study. All the selected subjects underwent thorough clinical examination to exclude any other disorder or chronic illness. Blood samples were collected at room temperature by veiw puncture without anticoagulant. Serum was separated after complete clot retraction and stored at 20 0 C until further analysis. PSA ESTIMATION Serum PSA was estimated by one step double monoclonal antibody enzyme linked immunoadsorbent assay (ELISA), using streptavidin coated tubes (Roche Enzymun-Test) by ELISA tube reader. The assay mixture contained 50 µl of calibrator or quality control serum or patient s serum, 1µl of the reagent Indian Journal of Clinical Biochemistry, 2004 132

containing primary biotinylated monoclonal antibodies to PSA and secondary antibody conjugated to peroxidase. The reaction mixture was incubated for one and half hours at room temperature. The supernatant was discarded and the antigen-antibody complex immobilized on to the bottom of tube was washed thrice with wash solution to remove unbound antibodies. To this, 1µl of the substrate solution containing di-ammonium 2,2 -azino bis 3- ethylbenzothiazoline-6-sulphonate was added and the tube was incubated for one hour at room temperature. The intensity of bluish green color was measured at 405 nm. PSA concentration was directly proportional to the intensity of the color developed. Statistical analysis was performed by student t test. Confidence intervals low-high mean, median, minimum and maximum were calculated for each decade age subgroups. Confidence interval low represented 5 th percentile value and confidence interval high represented 95 th percentile value in a given group. RESULTS The results of serum PSA concentrations in sera of 583 healthy males are presented in Table1. The maximum concentration of serum PSA in healthy males aged between 19 to 98 years was found to be 6.1ng/ ml. The mean, median and 95 percentile PSA value for all age groups were 1.4ng/ml, 1.0ng/ml and 1.5ng/ml respectively. The PSA could not be detected in sera of 3.08% of healthy men in our study. PSA is more than 4 ng/ml in 14 persons out of 583 (2.4%). The results on decade wise sub grouping of healthy men are presented in Table 1. The mean PSA value increased from 0.664 ng/ml for men younger than 30 years to 2.02 ng/ml for men older than 80 years. The 95 percentile value (the upper limit of normal range) rose from 1.07ng/ml for 20-29 years age group to 2.47 ng/ml for the older group (>80 years). The interesting thing to note was progressively significant increase in mean and median PSA concentration with advancing age right from 20 to 89 years. The maximum concentrations of serum PSA also increased progressively from1.7ng/ml to 6.1ng/ml for age groups 20-29 to 70-79 years. The maximum value of 5.0 ng/ml in men of more than 80 years was low compared to 70-79 years group. Contrary to this 95 percentile value was higher (2.47 ng/ml) in more than 80 years group compared to70-79 (2.0 ng/ml) years group. DISCUSSION Comparative data from world s literature on serum PSA reference values in healthy subjects of different populations have clearly shown slight but striking variations. Reports from different countries have documented serum PSA reference values either as minimum and maximum value or mean or 95 percentile (as upper limit of normal range) or a median value for their healthy subjects. In our study the results are presented as minimum, maximum, mean, median, lower and upper limit of 95 confidence intervals or percentile. Myrtel et al (3) found that 100% of healthy men less than 40 years of age and 97% of men 40 years or older had a serum PSA of below than or equal to 4.0 ng/ml. Of the 3% of men 40 years or older, none had a PSA value greater than 10 ng/ml. Investigators at John Hopkins hospital used mean ±3 standard deviations and reported upper limit of normal as 2.0 ng/ml for men less than 40 years of age and 2.8 ng/ml for men older than 40 years without any prostatic disease (1,7). Stamey et al (8) and Yang (9) established upper limit of reference ranges as 2.5 ng/ml (mean±2s.d) for 157 normal men (21 to 76 years) without any existing prostatic problem including BPH. An international multicentre study coordinated by M/s Boerhinger Mannheim from Germany in 1996 (10) covered more than 70 centres including ours from18 countries (Austria, Canada, Czechin, France, Germany, India, Israel, Italy, Japan, KSA-Saudi Arabia, Netherlands, New Zealand, Poland, Portugal, South Africa, Spain, Sweden, Turkey and UK). The estimation of serum PSA in 1063 asymptomatic healthy men revealed a minimum serum PSA value as 0.001 and maximum as 14.8 ng/ml. The median total PSA concentration for all ages was 0.77 ng/ml. Surprisingly this study did not document mean or 95 percentile value. While carrying out multicentre multidisciplinary project of American Cancer Society National Cancer Detection programme, Mettlin et al (11) observed mean serum PSA as 2.1ng/ml on 2011 healthy American white participants with mean average age of 64.5±5.0 years. The average median PSA concentration for all age groups in our study was 1.0 ng/ml for 583 healthy men contrary to BM multicentre study. Enormous efforts were made from 1995 onwards to establish age specific reference ranges for serum PSA throughout the world in order to find out serum PSA variation in different populations. Extensive work by Osterling group (4,12,13) on American whites and Japanese men clearly showed age specific significant increase for 95 percentile (upper limit of normal range of serum PSA) with advancing age (4,12). These results clearly show that one cannot rely on a single reference for all age groups and hence emphasis was made to establish age specific reference ranges for different populations (Table 2). Oesterling(12) showed that 95 percentile values in healthy Japanese from small fishing village of Shimamaki-mura, Japan were comparatively lower in all decade wise age subgroups compared to PSA concentration in American white men. Crawford et al (6) observed similar results on American whites during the prostate cancer awareness weak. Further studies by Catalona and Weinrich (14,15) revealed more or less similar results on US white population. From these reports it is evident that the 95 Indian Journal of Clinical Biochemistry, 2004 133

percentile, the upper limit of normal PSA correlated well with advancing age. The published reports (15,16) have shown higher 95 percentile i.e., the upper limit of normal range in American blacks compared to American white men. The serum PSA concentrations were lower in Japanese, Chinese, Indians and in Singaporeans compared to Americans (12,17-19). Interestingly Indian males had very low concentrations of PSA compared to healthy males from other Asia pacific countries. The lower limit of normal range in all populations did not show any value as in many subjects the PSA could not be detected by a given immunoassay method. However the current third generation immunoassays based on chemiluminescence technology are able to detect today a minimum concentration 0.006 ng/ml in healthy sera. Minimum value of PSA is for normal reference intervals shown as zero throughout the globe in many reports. Healthy men from and US and Turkey had higher mean serum PSA compared to many other populations in all age groups (20-22,6). Our results for mean serum PSA in healthy Indian males were slightly higher compared to men from Korea, but slightly lower than American men at different age groups relatively. During health fair of the midlands in US it was noted that 1716 American white men residing in Nebraska, U.S. (22) had slightly variable 95 percentile PSA concentrations compared to American white men residing in other parts of U.S. (22). The observations made in a community based study during prostate cancer awareness week during 1993 and 1994 revealed similar mean serum PSA concentrations in Indians and American white men (Table 2) residing in Denver USA in the 50-59 and 60-69 years age groups (23). The 95 percentile serum PSA concentrations reported by Lin et al (17) and Kao et al (18) for Taiwanese and Chinese have shown higher values compared to Singaporean men of all age groups except for men between 70-79 years. Korean and Singaporean men have shown similar 95 percentile PSA values for all age groups (19,20,24). Two centers have reported significantly higher concentration of serum PSA in American blacks compared to American whites (15,16). The cut off value of 4 ng/ml as upper limit of normal reference interval has been widely used by many groups, but this value does not take into account the age related increase in serum PSA. Our results on Indian men substantiated that there is an increase of PSA with advancing age. Hence the routine use of age specific reference intervals for PSA will improve the diagnostic efficiency in prostate cancer patients from India and will help in segregating individuals carrying high risk of harboring very early focus of prostate malignancy. In summary all the groups of workers including U.S. have shown age specific significant increase of serum PSA concentration variability among different ethnic and racial groups. These age specific reference ranges have the potential to make serum PSA a mere discriminating tumor marker for men and sensitive tumor marker for men below 60 years of age and a more specific tumor marker for men above 60 years of age. Additionally age specific serum PSA will help in developing specific algorithms for different populations to detect non-palpable adenocarcinoma of prostate at very early stage. This could be achieved by serial determinations of serum PSA at appropriate intervals if the individual had serum PSA concentration beyond 95percentile value specific for decade wise age subgroups. Table 1: Age Specific PSA in Healthy Males PSA 20-29 30-39 40-49 50-59 60-69 70-79 80-89 All (ng/ml) (A) (B) (C) (D) (E) (F) (G) ages N 40 52 58 148 164 86 35 583 Mean 0.664 0.972 1.14 1.31 1.414 1.67 2.02 1.4 ±SD ±0.41 ±0.516 ±0.76 ±1.074 ±1.23 ±1.497 ±1.19 ±1.24 Median 0.8 0.9 1.2 1.0 1.0 1.23 2.2 1.0 SEM 0.11 0.07 0.102 0.09 0.096 0.165 0.205 0.056 Lower 0.6 0.84 0.98 1.13 1.23 1.35 1.64 1.3 95% CI Upper 1.07 1.13 1.39 1.48 1.609 2.0 2.47 1.51 95%CI Min-Max 0-1.7 0-2.2 0-2.9 0-4.8 0-5.5 0-6.1 0-5.05 0-6.1 P - A vs B B vs C C vs D D vs E E vs F F vs G 0.0687 0.0028 0.0017 0.047 0.0166 0.0674 - Indian Journal of Clinical Biochemistry, 2004 134

Table 2: Age Specific Serum PSA (ng/ml) in Different Populations Author Population < 40 40-49 50-59 60-69 70-79 >80 (Year, n) (yrs) (yrs) (yrs) (yrs) (yrs) (yrs) PSA 95 PERCENTILE VALUE Oesterling et al Caucasians - 2.5 - - 6.5 - (1987) Oesterling et al Whites - 2.5 3.5 4.5 6.5 - (1993,n=471) Dalkin et al US - 3.5 5.4 6.3 - (1993,n=728) (Tuscan) Anderson et al US - 1.5 2.6 4.4 7.5 - (1995,n=1716) Nebraska Weinrich et al US Blacks - 1.9 3.8 5.7 - - (1998,n=1319) US Whites - - 2.7 4.9 - - Cooney et al Afro-Americans - 2.36 - - 5.59 (2001,n=432) Morgan et al AfroAmericans US - 2.4 6.54 11.3 12.5 - (1996,n=B-1673 Whites - 2.1 3.6 4.3 5.8 - W-1802) Lee et al Korean - 2.0 2.4 3.9 6.3 - (2000,n=5805) Oesterling et al Japanese - 2 3 4 5.0 (1995,n=286) Lin et al Chinese 1.9 2.59 3.31 5.03 5.73 - (1996,n=1008) (Taiwan) Kao et al Chinese 1.5 1.88 2.37 4.82 5.86 (1997,n=414) Saw et al Singaporean 1.4 1.7 2.3 4.0 6.3 6.6 (2000) Our Study Indians 0.9 1.3 1.48 1.6 2.0 2.47 (2002,n=583) PSA MEAN VALUES Stamey et al American 1.2 1.19 1.2 1.15 - - (1987,n=157) Yang et al American 0.95 1.19 1.2 1.15 - - (1987) Dalkin et al US - - 1.32 1.91 2.36 - (1993,n=728) (Tuscan) ±1.1 ±1.72 ±1.98 Dalkin et al US - - 3.9-7.6 - (1995,n=5469) Multicenter Atalay et al Turkey - 1.7 2.0 2.9 3.5 - (1998) Crawford et al US - 1.5 1.6 3.1 3.3 - (1993) Anderson et al US - 1.5 2.5 4.5 7.5 - (1995,n=1716) De Antoni et al US - 0.79 1.33 1.94 2.35 - (1996) (Denver) BM Intl.Multi Global 0.73 0.73 1.0 1.35 1.63 - Center study (1996,n=1032) Lee et al Korean 0.8 0.8 0.9 1.0 1.3 - (2000,n=1008) Our Study Indian 0.826 1.14 1.31 1.413 1.68 2.01 (2002,n=546) ±0.5 ±0.76 ±1.07 ±1.23 ±1.5 ±1.19 Indian Journal of Clinical Biochemistry, 2004 135

REFERENCES 1. Rock, R.C., Chan, D.W., Bruzek, D., Waldron, C., Oesterling, J.E. and Walsh,P.(1987) Evaluation of a monoclonal immuno-radiometric assay for prostate-specific antigen. Clin. Chem. 33, 2257-2261. 2. Ercole, C.J., Lange, P.H., Mathisen, M., Chiou, R.K., Reddy, P.K. and Vessella, R.L. (1987) Prostate specific antigen and prostatic acid phosphatase in the monitoring and staging of patients with prostatic cancer. Am. J. Urol.138, 1181-1184. 3. Myrtle, J.F. (1989) Normal levels of prostate specific antigen (PSA) In: Clinical Aspects of Prostate /cancer. Elsevier Science Publishing Company, New York, 183-189. 4. Oesterling, J.E., Jacobson, S.J., Chute, C.G., Guess, HA., Girman, C.J., Panser, L.A. and Lieber, M.M. (1993) Serum prostate specific antigen in a community-based population of healthy men: Establishment of age-specific reference ranges. JAMA. 270, 860. 5. Dalkin, B.L., Ahmann, F. and Southwick, P. (1993) Derivation of normal prostate-specific antigen (PSA) level by age. J.Urol.149,413A. 6. Crawford, E.D.(1993) Report on the 1992 Prostate Cancer Awareness week. J. Urol. 149, 55A. 7. Chan, D.W., Bruzek, D.J., Osterling, J.E., Rock, R.C. and Walsh, P.C. (1987) Prostate-specific antigen as a marker for prostatic cancer: a monoclonal and polyclonal immunoassay compared Clin. Chem.33, 1916. 8. Stamey, T.A., Yang, N., Hay, A.R., McNeal, J.E., Freiha, F.S. and Redwine, E. (1987) Prostatespecific antigen as a serum marker for adenocarcinoma of the prostate. New Engl. J. Med.317, 909-916. 9. Yang, N. (1989) Pros-Check PSA: a double antibody radioimmunoassay for prostatespecific antigen. In: Clinical Aspects of Prostate Cancer. Edited by W.J. Catalona, D.S. Coffey abd J.P. Karr. Elsevier Science Publishing Company, New York. 172-178. 10. BM Multicentre International study PSA free (1996), Boerhringer Mannheim Lab Diagnostics, Mannheim, Germany. 11. Curtis Mettlin., Peter, J. Littrup., Robert, A. Kane., Gerald, P. Murphy., Fred Lee., Arthur Chesley., Robert Badalament and Fatollah, K. Mostofi. (1994) Relative Sensitivity and Specificity of Serum Prostate Specific Antigen (PSA) Level compared with Age-Referenced PSA, PSA Density, and PSA Change- Data from the American Cancer Society National Prostate Cancer Detection Project. Cancer 74, 1615-1619. 12. Oesterling, J.E., Kumamoto, Y., Tsukamoto, T., Girman, C.J., Guess, H.A., Masumori, N., Jacobsen, S.J. and Lieber, M.M. (1995) Serum protstate-specific antigen in a communitybased population of healthy Japanese men: lower values than for similarly aged white men. Br. J. Urol. 75, 347-353. 13. Thomas, D. Richardson and Oesterling, J.E. (1997) Age-specific reference ranges for serum prostate-specific antigen. Urol. Clin. N. Am. 24, 2, 339-364. 14. Catalona, W.J., Hudson, M.A., Scardino, P.T., Richie, J.P., Ahmann, F.R., Flanigan, R.C., dekernion, J.B., Ratliff, T.L., Kavoussi, L.R. and Dalkin, B.L. (1994) Selection of optimal prostate specific antigen cutoffs for early detection of prostate cancer: receiver operating characteristic curves. J.Urol. 152, 2037-2042. 15. Weinrich, M.C., Jacobsen, S.J., Weinrich, S.P., Moul, J.W., Oesterling, J.E., Jacobson, D. and Wise, R. (1998) Reference ranges for serum prostate-specific antigen in black and white men without cancer. Urology 52, 967-973. 16. Ted Morgan, O., Steven, J., Jacobsen., W.F., McCarthy, D.J., Jacobson., D.G., McLeod and Judd, W.M. (1996) Age Specific reference ranges for serum prostate specific Antigen in Black Men. New Engl. J. Med. 335, 304-310. 17. Lin, W.Y., Gu, C.J., Kao, C.H., Changlai, S.P. and Wang, S.J. (1996) Serum prostate-specific anntigen in healthy Chinese men: establishment of age-specific reference ranges. Neoplasma 43, 103-105. 18. Kao, C.H. (1997) Age-related free PSA, total PSA and free PSA/total PSA ratios: establishment of reference ranges in Chinese males. Anticancer Res. 17, 1361-1365. 19. Saw, S. and Aw, T.C. (2000) Age-related reference intervals for free and total prostatespecific antigen in a Singaporean population. Pathology 32, 245-249. 20. Lee, S.E., Kwak, C., Park, M.S., Lee, C.H., Kang, W. and Oh, S.J. (2000) Ethnic differences in the age-related distribution of serum prostate- Indian Journal of Clinical Biochemistry, 2004 136

specific antigen values: a study in healthy Korean population. Urology 56, 1007-1010. 21. Atalay, A.C., Karaman, M.I., Guney, S., Dalkilic, A. Muslumanoglu, A.Y. and Ergenekon, E. (1998) Age-specific PSA reference ranges in a group of non-urologic patients. Int. Urol. Nephrol. 30, 587-591. 22. Anderson, J.R., Strickland, D., Corbin, D., Byrnes, J.A. and Zweiback, E. (1995) Age specific reference ranges for serum prostatespecific antigen. Urology 46,54-57. 23. DeAntoni, E.P., Crawford, E.D., Oesterling, J.E., Ross, C.A., Berger, E.R., McLeod, D.G., Staggers, F. and Stone, N.N. (1996) Age-and race-specific reference ranges for prostatespecific antigen from a large community-based study. Urology 48, 234-239. 24. Cooney, K.A., Strawderman, M.S., Wojno, K.J., Doerr, K.M., Taylor, A., Alcser, K.H., Heeringa, S.G., Taylor, J.M., Wei, J.T., Montie, J.E and Schottenfeld, D. (2001) Age-specific distribution of serum prostate-specific antigen in a community- based study of African-American men. Urology 57, 91-96. Indian Journal of Clinical Biochemistry, 2004 137